Alexion Pharmaceuticals, Inc. (ALXN)

182.50
Prev Close 182.50
Day Low/High 0.00 / 0.00
52 Wk Low/High 99.91 / 187.45
Exchange
Div & Yield N.A. (N.A)
Rules of the Game: Further on Free Cash Flow

Rules of the Game: Further on Free Cash Flow

This metric is a prime indicator of financial health, and these health-related stock stand out.

Fitz Bits: Google Primed to Buy

Fitz Bits: Google Primed to Buy

The stock may now be at a tradable low -- but keep your stop tight.

Two Pharma Stocks Enjoying Good Health

Two Pharma Stocks Enjoying Good Health

These large-cap companies have topped expectations for four quarters and are projected to again report robust earnings.

Healthcare Holds Firm

Healthcare Holds Firm

The entire sector did well withstanding Tuesday's decline, but here are a few standouts.

Alexion rated new Neutral at Lazard

Fitz Bits: A Stalwart Uptrend

Fitz Bits: A Stalwart Uptrend

Use this Alexion pullback as a buying opportunity.

The Week Ahead: GDP Data, Earnings

The Week Ahead: GDP Data, Earnings

Contributor Ken Shreve takes a look at economic data and earnings reports scheduled for this week.

Biotech Is a Source of Buys

Biotech Is a Source of Buys

Alexion shows one of the most bullish long-term charts in my database.

Daily Recap of the Charts June 15

Daily Recap of the Charts June 15

Mark Sperling of T3Live review the day's market action and sets up your trading plan for the next session.

Big-Cap Health Care Winners

Big-Cap Health Care Winners

Alexion Pharmaceuticals and Intuitive Surgical are leaders in a top-performing sector.

Sitting Tight for Respectable Volume

Sitting Tight for Respectable Volume

The light volume keeps me hesitant, though here are a few recent standout names.

Bull Market in Biotech

Bull Market in Biotech

The biotechnology sector has weathered the correction and looks ready to push higher.

Fitz Bits: More Quick Bites

Fitz Bits: More Quick Bites

Here's another serving of buy-on-the-bounce trades

Mo-Mos Lose Their Mojo

Mo-Mos Lose Their Mojo

Momentum stocks are under fairly severe pressure.

The Week Ahead: Housing Data, GDP and Earnings

The Week Ahead: Housing Data, GDP and Earnings

Contributor Ken Shreve takes a look at economic data and earnings reports scheduled for the coming week.

Not for the Faint of Heart

Not for the Faint of Heart

The high-fliers I have been showing can reap huge returns, but make sure you can handle the volatility.

Fitz Bits: Stay Long Alexion

Fitz Bits: Stay Long Alexion

The shares are highly likely to test $100. Just keep a trailing stop on any existing positions.

Look for Resting Stocks

Look for Resting Stocks

The virtuous cycle of overrunning price targets is in effect.

Alexion Pharmaceuticals upgraded at UBS

The Cure for Alexion

With only one drug on the market, the pharmaceutical company is expanding its pipeline.

The Day Ahead: Pulling Back

The Day Ahead: Pulling Back

News that Greece will need further austerity measures dragged down world markets and U.S. futures.